Somatic BRCA1 loss-of-function in metastatic PDAC: POLO trial restricted to germline; som...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRCA1-SOMATIC-PDAC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PDAC |
| Sources | SRC-CIVIC SRC-ESMO-PANCREATIC-2024 SRC-NCCN-PANCREATIC-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | BRCA1 somatic loss-of-function |
| Disease | DIS-PDAC |
| ESCAT tier | IIA |
| Recommended combinations | platinum-based chemo (FOLFIRINOX preferred), olaparib maintenance (off-label, NCCN-listed) |
| Evidence summary | Somatic BRCA1 loss-of-function in metastatic PDAC: POLO trial restricted to germline; somatic data limited but smaller series suggest similar PARPi sensitivity. NCCN allows PARPi consideration off-label in sBRCA PDAC. ESCAT IIA / OncoKB Level 3A. |
Notes
Reflex germline testing recommended. Somatic-only not labeled for olaparib maintenance in PDAC.
Used By
No reverse references found in the YAML corpus.